What They Do
HIMS operates a direct-to-consumer digital health platform providing telehealth services and treatments for sensitive health conditions like sexual health, hair loss, weight management, and mental wellness. They connect patients with licensed healthcare providers through their app and website, then ship FDA-approved medications and treatments directly to consumers' doors. The company monetizes through subscription-based recurring revenue from over 2.5 million subscribers who pay an average of $83 monthly.
Investment Thesis
**Explosive growth trajectory** — Revenue surged 59% YoY to $2.35B in 2025 with 2.5M+ subscribers, driven by expanding into high-demand specialties like weight loss (70+ YoY growth) and launching three new $100M+ revenue potential categories**International expansion opportunity** — $1.15B Eucalyptus acquisition opens Australia, Japan, and deeper European markets, with international revenue already growing ~400% YoY to $134M and targeting $1B+ within 3 years**Diversified beyond regulatory risk** — Despite GLP-1 scrutiny, majority of revenue comes from non-weight loss offerings across sexual health, hair loss, mental wellness, with 65% of subscribers using personalized treatments driving higher retentionKey Risks
**Regulatory uncertainty around compounded GLP-1s** — Ongoing scrutiny of weight loss treatments could impact a fast-growing revenue segment, though management emphasizes business diversification**Intense competition and customer acquisition costs** — Marketing still represents 39% of revenue despite improvement, and faces competition from traditional healthcare and other D2C platforms in crowded telehealth spaceGrowth Story
Revenue is projected to grow 17-24% in 2026 to $2.7-2.9B, building on 2025's 59% surge driven by specialty expansion and international markets. The company is targeting massive addressable markets across 10+ health specialties, with new launches like testosterone support and menopause treatments each representing $100M+ annual opportunities. International expansion through acquisitions positions HIMS to capture global demand for accessible, stigma-free healthcare delivery.
Profitability Profile
Gross margins remain healthy at 59-72% with improving operational leverage as marketing efficiency gains 7 percentage points YoY. Adjusted EBITDA surged 80% to $318M (14% margin) in 2025 with positive operating cash flow of $300M, demonstrating the subscription model's cash generation power. The company has achieved consistent net income profitability while investing heavily in growth, with 2026 EBITDA margins expected around 12% at guidance midpoint.
Competitive Position
HIMS has built a distinctive brand around destigmatizing sensitive health conditions with a consumer-friendly, direct-pay model that bypasses traditional insurance hassles. They compete against traditional telehealth players like Teladoc and specialty-focused competitors, but differentiate through their integrated approach combining telehealth consultations, prescription fulfillment, and ongoing care management. Their scale advantages in marketing and logistics create barriers for smaller competitors, while rapid specialty expansion broadens their healthcare ecosystem moat.
Recent Momentum
Q4 2025 showed continued strong execution with 28% revenue growth and successful launch of three major new specialties, though guidance suggests some moderation in growth rates for 2026. The company completed its largest acquisition ever with Eucalyptus ($1.15B) and maintained ambitious 2030 targets of $6.5B revenue despite regulatory headwinds. Recent quarters have shown consistent earnings beats, though revenue performance has been mixed with some misses in recent quarters.
What Wall Street Thinks
Analysts appear cautiously optimistic about the growth trajectory and international expansion strategy, though there's likely debate around valuation given the premium multiple and regulatory risks in weight management. The consistent profitability and strong cash generation provide confidence, but growth rate moderation in 2026 guidance may temper near-term enthusiasm. The Eucalyptus acquisition and specialty expansion demonstrate management's ability to execute on growth investments.
The Bottom Line
HIMS has evolved from a niche men's health startup into a diversified digital healthcare platform with proven ability to scale new specialties and expand internationally, but investors must weigh the compelling growth story against regulatory risks and increasing competition for consumer attention in telehealth.
